KNSA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

196.64M

+60.47%

0.420

-450.01%

204.04M

+48.08%

0.330

+200%

215.69M

+37.56%

0.380

+65.22%

Estimates Revision

The market is revising Upward the revenue expectations for Kiniksa Pharmaceuticals International, plc (KNSA) for FY2025, with the revenue forecasts being adjusted by 5.1% over the past three months. During the same period, the stock price has changed by 8.93%.

Revenue Estimates for FY2025

Revise Upward

+5.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-5.15%

In Past 3 Month

Stock Price

Go Up

+8.93%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 52.00 USD with a low forecast of 44.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

44.00

Averages

52.00

High

60.00

Current: 0.000

Low

44.00

Averages

52.00

High

60.00

Goldman Sachs

Buy

upgrade

$45 -> $55

2025-10-29

Reason

Goldman Sachs

Price Target

$45 -> $55

2025-10-29

upgrade

Buy

Reason

Goldman Sachs raised the firm's price target on Kiniksa to $55 from $45 and keeps a Buy rating on the shares.

Citi

Geoff Meacham

Buy

maintain

$45 -> $50

2025-10-17

Reason

Citi

Geoff Meacham

Price Target

$45 -> $50

2025-10-17

maintain

Buy

Reason

Citi analyst Geoff Meacham raised the firm's price target on Kiniksa to $50 from $45 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.

TD Cowen

Buy

initiated

$60

2025-09-29

Reason

TD Cowen

Price Target

$60

2025-09-29

initiated

Buy

Reason

TD Cowen initiated coverage of Kiniksa with a Buy rating and $60 price target. The firm says Kiniksa is at a \"pivotal stage\" as Arcalyst's launch continues to ramp while KPL-387 could offer more favorable dosing. This could extend the franchise and significantly improve the company's earnings, the analyst tells investors in a research note.

Jefferies

Buy

maintain

$45 -> $54

2025-07-29

Reason

Jefferies

Price Target

$45 -> $54

2025-07-29

maintain

Buy

Reason

Jefferies raised the firm's price target on Kiniksa to $54 from $45 and keeps a Buy rating on the shares after what the firm points out was "another 'beat & raise'" report following a "greatly positive" Q1. The firm sees strong commercial execution, continued growth on all launch metrics, and meaningful upside from further deepening the penetration into the target population as well as potential expansion into a larger population of patients, the analyst tells investors.

Wells Fargo

NULL -> Overweight

upgrade

$30 -> $42

2025-07-09

Reason

Wells Fargo

Price Target

$30 -> $42

2025-07-09

upgrade

NULL -> Overweight

Reason

Wells Fargo raised the firm's price target on Kiniksa to $42 from $30 and keeps an Overweight rating on the shares. The firm's Q2 Arcalyst estimates of $146M are in line with the Street, and it forecasts continued growth through 2025. As KPL-387's trial initiates in mid-25, all eyes are on Arcalyst this year and its market share in early lines, adds Wells.

Wedbush

David Nierengarten

Buy

Reiterates

$34

2025-04-16

Reason

Wedbush

David Nierengarten

Price Target

$34

2025-04-16

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA.O) is 27.82, compared to its 5-year average forward P/E of -289.78. For a more detailed relative valuation and DCF analysis to assess Kiniksa Pharmaceuticals International PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-289.78

Current PE

27.82

Overvalued PE

978.94

Undervalued PE

-1558.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-26.42

Current EV/EBITDA

20.12

Overvalued EV/EBITDA

123.79

Undervalued EV/EBITDA

-176.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.31

Current PS

3.78

Overvalued PS

16.79

Undervalued PS

-2.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KNSA News & Events

Events Timeline

No data

News

9.0

2025-11-19NASDAQ.COM

From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?

5.0

2025-10-22Yahoo Finance

Kiniksa Pharmaceuticals Executive Offloads Shares Valued at $1,962,781, Recent SEC Filing Reveals

3.0

2025-10-22NASDAQ.COM

Analysis Indicates VBK Could Reach $342

People Also Watch

Frequently Asked Questions

What is Kiniksa Pharmaceuticals International PLC (KNSA) stock price today?

The current price of KNSA is 41.73 USD — it has decreased -1.63 % in the last trading day.

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s business?

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

What is the price predicton of KNSA Stock?

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s revenue for the last quarter?

Kiniksa Pharmaceuticals International PLC revenue for the last quarter amounts to 180.86M USD, increased 61.17 % YoY.

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s earnings per share (EPS) for the last quarter?

Kiniksa Pharmaceuticals International PLC. EPS for the last quarter amounts to 0.23 USD, decreased -227.78 % YoY.

What changes have occurred in the market's expectations for Kiniksa Pharmaceuticals International PLC (KNSA)'s fundamentals?

How many employees does Kiniksa Pharmaceuticals International PLC (KNSA). have?

Kiniksa Pharmaceuticals International PLC (KNSA) has 315 emplpoyees as of January 08 2026.

What is Kiniksa Pharmaceuticals International PLC (KNSA) market cap?

Today KNSA has the market capitalization of 3.16B USD.